According to the World Health Organization (WHO), lenacapavir offers a highly effective, long-acting alternative to daily ...

Tarava’s story illustrates the remarkable progress Zimbabwe has made in tackling the HIV crisis. Once ravaged by soaring ...

Year's supply of injectable to cost Rs 3,549, compared to over Rs 17 lakh in US. Powerful alternative to daily oral PrEP, ...

Cuts proposed by the Trump administration and House Republicans could drive up new HIV cases by more than 200,000 by 2030, ...

New study findings could change treatments for HIV in young children. HIV remission may be possible for very young children ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Indian drugmakers Dr Reddy's Laboratories and Hetero Labs said on Wednesday that they will sell generic versions of a new and ...

Learn about Christopher Green's journey with HIV, the stigma surrounding the disease, and the systemic inequities that drive disparities in the South.

As HIV diagnoses continue increasing in metro Atlanta, the number of dollars for research and treatment is going down.

“We’ve seen a 214 % increase regionally, from a 5-year period to the previous 5- year period.” Historically marginalized groups that include minorities, the LGBTQ community and low-income populations ...

Dr. Brandon Hill, CEO of Vivent Health and a researcher in HIV and sexual issues, talks about changes in government funding.

Knowing how to leverage these technologies means we can help set the new standard and inform the next evolution of HIV care.